切口路径失活使乳腺癌干细胞对化学疗法敏感,使用NIR光敏纳米粒子
Yuwei Liu1,2,3, Yang Zhou1,2,3, Yunong Li1,2,3
1State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China.
ACS applied materials & interfaces
|December 17, 2024
概括
这项研究将帕克利塔塞尔化疗与通过近红外线传递的Notch抑制剂结合起来,以向癌症干细胞并减少瘤异质性. 这种方法提高了化疗的有效性,并防止复发.
科学领域:
- 在瘤学瘤学.
- 生物医学工程 生物医学工程
- 癌症干细胞研究研究
背景情况:
- 化疗的有效性受到固体瘤异质性的限制.
- 癌症干细胞 (CSCs) 通过自我更新和分化驱动内异质性.
- 现有治疗方法在全身副作用和非特异性干性抑制方面扎.
研究的目的:
- 破坏CSC介导的癌症异质性,并使固体瘤对帕克利塔塞尔 (PTX) 敏感.
- 开发一种针对性药物输送系统,用于联合化疗和Notch信号抑制.
- 提高治疗疗效,防止瘤复发,同时最大限度地减少全身毒性.
主要方法:
- 帕克利塔塞尔 (PTX) 和马分泌酶抑制剂LY-411,575同时使用近红外 (NIR) 光控制系统.
- 针对性调节Notch信号通路,特别是在瘤部位.
- 评估治疗疗效,预防瘤复发和全身副作用.
主要成果:
- 实现了分化的癌细胞和未分化的CSC的向除.
- 通过NIR控制的Notch通路调节,通过NIR控制的Notch通路调节显著提高化疗疗效.
- 观察到明显的术后瘤复发的预防,系统性副作用最小化.
结论:
- 组合策略有效地破坏了CSC介导的癌症异质性.
- 通过NIR光控制的药物递送增强了帕克利塔塞尔的疗效,并防止了瘤复发.
- 这种方法为癌症治疗中的马分泌酶抑制剂临床转化所面临的挑战提供了有希望的解决方案.
更多相关视频
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.2K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
相关概念视频
Notch Signaling Pathway
4.2K
The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
4.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.1K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
